SynthesisGut microbes
Robust cross-cohort gut microbiome associations with COVID-19 severity.
Synthesis in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Association Between Gut Microbiota and Pneumonia Risk: A Systematic Review and Mendelian Randomization.International journal of medical sciences · 2025Pooled it
- Exploring shotgun metagenomic data to detect microeukaryotic pathogens in wildlife.BMC microbiology · 2026Article
- Gut microbiota impact on lung diseases: a mini review of clinical evidence.Infection and immunity · 2026Review
- The Role of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy in Improving Type 2 Diabetes Through Modulation of Gut Microbiota and Metabolites.Obesity surgery · 2026Review
- Fecal short-chain fatty acids and serum metabolites: the impact of COVID-19 infection on dialysis patients.Frontiers in nutrition · 2026Article
- Integrative metagenomics and metabolomics reveal age-associated gut microbiota and metabolite alterations in a hamster model of COVID-19.Gut microbes · 2025Article
- Metaproteomics reveals age-specific alterations of gut microbiome in hamsters with SARS-CoV-2 infection.Gut microbes · 2025Article
- Significance of neutrophil extracellular traps and low-density granulocytes in advanced chronic kidney disease (stage 5D) cases with COVID-19.Renal failure · 2025Article
- Gut Microbiome Dysbiosis in COVID-19: A Systematic Review and Meta-Analysis of Diversity Indices, Taxa Alterations, and Mortality Risk.Microorganisms · 2025Review
- Microbiome and Long COVID-19: Current Evidence and Insights.International journal of molecular sciences · 2025Review
- Gastric Cancer and Microbiota: Exploring the Microbiome's Role in Carcinogenesis and Treatment Strategies.Life (Basel, Switzerland) · 2025Review
- Deciphering respiratory viral infections by harnessing organ-on-chip technology to explore the gut-lung axis.Open biology · 2025Review
- Role of Gut and Urinary Microbiome in Children with Urinary Tract Infections: A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Review
- In Silico Analysis of Probiotic Bacteria Changes Across COVID-19 Severity Stages.Microorganisms · 2024Article
- Cross-Cohort Gut Microbiome Signatures of Irritable Bowel Syndrome Presentation and Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Disease-associated microbiome signature species in the gut.PNAS nexus · 2024Article
- The gut-airway microbiome axis in health and respiratory diseases.Nature reviews. Microbiology · 2024Review
- Deciphering Microbial Shifts in the Gut and Lung Microbiomes of COVID-19 Patients.Microorganisms · 2024Article
- Alterations in microbiota of patients with COVID-19: implications for therapeutic interventions.MedComm · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although many recent studies have examined associations between the gut microbiome and COVID-19 disease severity in individual patient cohorts, questions remain on the robustness across international cohorts of the biomarkers they reported. Here, we performed a meta-analysis of eight shotgun metagenomic studies of COVID-19 patients (comprising 1,023 stool samples) and 23 > 16S rRNA gene amplicon sequencing (16S) cohorts (2,415 total stool samples). We found that disease severity (as defined by the WHO clinical progression scale) was associated with taxonomic and functional microbiome differences. This alteration in gut microbiome configuration peaks at days 7-30 post diagnosis, after which the gut microbiome returns to a configuration that becomes more similar to that of healthy controls over time. Furthermore, we identified a core set of species that were consistently associated with disease severity across shotgun metagenomic and 16S cohorts, and whose abundance can accurately predict disease severity category of SARS-CoV-2 infected subjects, with
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.